From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
EMPEROR-preserved [37] | ||
---|---|---|
Class and cardiovascular outcomes | HR (95% CI) | p-value |
Primary composite outcome | ||
 Composite of cardiovascular death or hospitalization for heart failure | 0.79 (0.69–0.90) | < 0.001 |
Secondary outcome | ||
 Total number of hospitalizations for heart failure | 0.73 (0.61–0.88) | < 0.001 |
Secondary outcome | ||
 Mean slope of change in eGFR per year—ml/min/1.73 m2 | 1.36 (1.06–1.66) | < 0.001 |
Other prespecified analyses | ||
 Change in KCCQ clinical summary score at week 52 | 1.32 (0.45–2.19) |  |
Other prespecified analyses | ||
 Total number of hospitalizations for any cause | 0.93 (0.85–1.01) |  |
Other prespecified analyses | ||
 Composite renal outcome | 0.95 (0.73–1.24) |  |
Other prespecified analyses | ||
 Onset of new diabetes in patients with prediabetes | 0.84 (0.65–1.07) |  |
Other prespecified analyses | ||
 Death from any cause | 1.00 (0.87–1.15) |  |
Adverse events | Event rate (%) active vs. placebo group | Â |
---|---|---|
Urinary tract infections | 9.9 vs. 8.1 | Â |
Genital infections | 2.2 vs. 0.7 | Â |
Hypotension | 10.4 vs. 8.6 | Â |